Glucocorticoid-induced Tumour Necrosis Factor Receptor Related Protein (GITR) in Rheumatoid Arthritis
NCT ID: NCT03763201
Last Updated: 2020-07-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
50 participants
OBSERVATIONAL
2018-11-08
2020-09-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Predictability Studies on the Efficacy of TNF-α Inhibitors in Chinese RA From "Real World"
NCT02878161
"Matrix Metalloproteinases 7 and 9 in Rheumatoid Arthritis Patients With Interstitial Lung Disease"
NCT07173582
Enthesitis Assessment Before and After Anti-Tumor Necrosis Factor Treatment in Spondyloarthritis
NCT04953871
Study To Evaluate The Impact Of Anti-Cyclic Citrullinated Peptide(Anti-CCP) For Management With Enbrel In Patients With Psoriatic Arthritis(PsA)
NCT04428502
Screening for Flare After b/tsDMARD Discontinuation in Rheumatoid Arthritis
NCT05119452
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study design: a longitudinal observational cohort study.
This study will be carried out on two groups:
* Group (I): fifty early onset rheumatoid arthritis (RA) patients fulfilled the 2010 American college of rheumatology (ACR) - European league against rheumatism (EULAR) classification criteria for RA \[11\].
* Group (II): Twenty healthy individuals of matching age and sex as control group.
Both groups will be recruited from the in-patients and out-patients' clinic of the Rheumatology, Rehabilitation\& Physical Medicine Department, Benha University Hospital.
All patients will be evaluated at baseline at 6 months follow up using:
(A) Clinical evaluation 1. Complete history taking. 2. Thorough clinical examination. 3. Disease activity using DAS28 \[12\]
(B) Laboratory assessment:
All patients will be subjected to the following measurements:
1. Erythrocyte sedimentation rate (ESR).
2. C reactive protein (CRP).
3. Rheumatoid factor (RF)
4. Anti-cyclic citrullinated peptide (Anti- CCP).
5. glucocorticoid-induced tumour necrosis factor receptor related protein (GITR)
(D) Musculoskeletal ultrasound assessment: Ultrasound examinations will be performed for patients and control groups using a Logiq e equipped with a broadband 8- to 13-MHz linear transducer
2. Statistical analysis The collected data will be tabulated and analyzed using suitable statistical computer version.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
rheumatoid arthritis
recently diagnosed rheumatoid arthritis patients in whom we measure Glucocorticoid-induced Tumour Necrosis Factor Receptor Related Protein (GITR) in their serum and synovial fluid (if clinically determined knee effusion)
measurement of GITR
serum and synovial fluid measurement of glucocorticoid-induced tumour necrosis factor receptor related protein
control group
age and sex matched healthy volunteers whom we measure Glucocorticoid-induced Tumour Necrosis Factor Receptor Related Protein (GITR) in their serum.
measurement of GITR
serum and synovial fluid measurement of glucocorticoid-induced tumour necrosis factor receptor related protein
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
measurement of GITR
serum and synovial fluid measurement of glucocorticoid-induced tumour necrosis factor receptor related protein
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
16 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Benha University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Waleed Ahmed Salaheldeen Hassan
Assistant professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Waleed A Hassan, MD
Role: PRINCIPAL_INVESTIGATOR
Benha university- Qaluibya- Egypt
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
bENHA UNIVERSITY HOSPITAL
Banhā, Qalyubia Governorate, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BenhaU 112018
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.